Failure of GPI compounds to display neurotrophic activity in vitro and in vivo

Citation
A. Bocquet et al., Failure of GPI compounds to display neurotrophic activity in vitro and in vivo, EUR J PHARM, 415(2-3), 2001, pp. 173-180
Citations number
29
Categorie Soggetti
Pharmacology & Toxicology
Journal title
EUROPEAN JOURNAL OF PHARMACOLOGY
ISSN journal
00142999 → ACNP
Volume
415
Issue
2-3
Year of publication
2001
Pages
173 - 180
Database
ISI
SICI code
0014-2999(20010316)415:2-3<173:FOGCTD>2.0.ZU;2-Q
Abstract
The aim of this study was to evaluate the neurotrophic and neuroprotective properties of a series of immunophilin ligands and to assess the potential involvement of FK506 Binding Protein 12 kDa (FKBP12) rotamase inhibition in this activity. Both FK506 and rapamycin induced a potent inhibition of the FKBP12 rotamase activity (pIC(50) values of 7.3 and 7.4, respectively) but only a modest inhibition was observed with 1-(3,3-dimethyl-2-oxo-pentanoyl )-pyrrolidine-2-carboxlic acid S-3-pyridin-3-yl-propyl ester (GPI 1046) (5. 8), its N-oxide (5.4) and thioester (6.3) analogues. Compared to nerve grow th factor, all these immunophilin ligands only induced marginal increases i n neurite outgrowth of rat dissociated newborn dorsal root ganglia cells. F urthermore, systemic administration of GPI 1046 and its N-oxide and thioest er analogues failed to prevent striatal dopamine depletion induced by acute or chronic i.p. treatment with 1-methyl4-phenyl 1,2,3,6 tetrahydropyridine (MPTP). These results suggest that inhibition of FKBP12 rotamase activity is not predictive for neurotrophic and neuroprotective properties of immuno philin ligands and question their therapeutic utility in neurodegenerative diseases like Parkinson's disease. (C) 2001 Elsevier Science B.V. All right s reserved.